Carnegie Investment Counsel’s Thermo Fisher Scientific TMO Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $18M | Sell |
35,925
-5,952
| -14% | -$2.86M | 0.36% | 78 |
|
|
2026
Q1 | $20.6M | Sell |
41,877
-5,590
| -12% | -$3.03M | 0.4% | 69 |
|
|
2025
Q4 | $27.5M | Sell |
47,467
-2,178
| -4% | -$1.23M | 0.51% | 55 |
|
|
2025
Q3 | $24.1M | Sell |
49,645
-2,768
| -5% | -$1.29M | 0.45% | 61 |
|
|
2025
Q2 | $21.3M | Sell |
52,413
-3,703
| -7% | -$1.55M | 0.43% | 68 |
|
|
2025
Q1 | $24.7M | Sell |
56,116
-2,835
| -5% | -$1.54M | 0.59% | 48 |
|
|
2024
Q4 | $30.7M | Buy |
58,951
+726
| +1% | +$399K | 0.88% | 24 |
|
|
2024
Q3 | $36M | Buy |
58,225
+3,372
| +6% | +$2M | 1.06% | 18 |
|
|
2024
Q2 | $30.3M | Buy |
54,853
+3,828
| +8% | +$2.19M | 0.95% | 22 |
|
|
2024
Q1 | $29.7M | Buy |
51,025
+1,584
| +3% | +$889K | 0.92% | 23 |
|
|
2023
Q4 | $26.2M | Sell |
49,441
-1,792
| -3% | -$867K | 0.9% | 24 |
|
|
2023
Q3 | $25.9M | Buy |
51,233
+4,954
| +11% | +$2.64M | 1% | 21 |
|
|
2023
Q2 | $24.1M | Buy |
46,279
+2,911
| +7% | +$1.57M | 0.89% | 25 |
|
|
2023
Q1 | $25M | Buy |
43,368
+3,914
| +10% | +$2.21M | 1% | 20 |
|
|
2022
Q4 | $21.7M | Buy |
39,454
+1,008
| +3% | +$534K | 0.93% | 25 |
|
|
2022
Q3 | $19.5M | Sell |
38,446
-188
| -0.5% | -$105K | 0.93% | 23 |
|
|
2022
Q2 | $21M | Sell |
38,634
-2,071
| -5% | -$1.14M | 0.95% | 24 |
|
|
2022
Q1 | $24M | Buy |
40,705
+2,071
| +5% | +$1.19M | 0.88% | 30 |
|
|
2021
Q4 | $25.8M | Sell |
38,634
-696
| -2% | -$435K | 0.85% | 30 |
|
|
2021
Q3 | $22.5M | Sell |
39,330
-737
| -2% | -$405K | 0.85% | 30 |
|
|
2021
Q2 | $20.2M | Buy |
40,067
+2,519
| +7% | +$1.19M | 0.76% | 40 |
|
|
2021
Q1 | $17.1M | Buy |
37,548
+1,004
| +3% | +$479K | 0.72% | 45 |
|
|
2020
Q4 | $17M | Buy |
36,544
+3,302
| +10% | +$1.55M | 0.77% | 40 |
|
|
2020
Q3 | $14.6M | Sell |
33,242
-1,279
| -4% | -$528K | 0.75% | 42 |
|
|
2020
Q2 | $12.5M | Buy |
34,521
+867
| +3% | +$291K | 0.72% | 43 |
|
|
2020
Q1 | $9.51M | Buy |
33,654
+8,860
| +36% | +$2.79M | 0.66% | 47 |
|
|
2019
Q4 | $8.05M | Buy |
24,794
+2,881
| +13% | +$874K | 0.46% | 69 |
|
|
2019
Q3 | $6.38M | Buy |
21,913
+638
| +3% | +$183K | 0.41% | 81 |
|
|
2019
Q2 | $6.25M | Buy |
21,275
+623
| +3% | +$172K | 0.41% | 75 |
|
|
2019
Q1 | $5.65M | Sell |
20,652
-113
| -0.5% | -$28.1K | 0.39% | 74 |
|
|
2018
Q4 | $4.65M | Buy |
20,765
+15,714
| +311% | +$3.69M | 0.43% | 71 |
|
|
2018
Q3 | $1.21M | Sell |
5,051
-32,130
| -86% | -$7.39M | 0.1% | 180 |
|
|
2018
Q2 | $8.19M | Buy |
37,181
+4,520
| +14% | +$959K | 0.62% | 50 |
|
|
2018
Q1 | $6.91M | Buy |
32,661
+5,429
| +20% | +$1.14M | 0.58% | 56 |
|
|
2017
Q4 | $5.36M | Buy |
+27,232
| New | +$5.22M | 0.48% | 66 |
|
Other funds holding TMO
RG
ECSS
LT
Carnegie Investment Counsel's TMO Position: Q2 2026 in Review
Carnegie Investment Counsel reduced its Thermo Fisher Scientific (TMO) stake by 14% in Q2 2026, selling an estimated $2.86M and leaving 35,925 shares worth $18M. The position accounts for 0.36% of the portfolio, ranked #78.
Carnegie Investment Counsel first reported a position in TMO in Q4 2017 and has held it in 35 quarters since. The position peaked at $36M in Q3 2024. 1,172 funds tracked by Wall St. Rank hold TMO as of Q2 2026.
- Carnegie Investment Counsel held 35,925 shares of Thermo Fisher Scientific worth $18M as of Q2 2026.
- Carnegie Investment Counsel sold 5,952 Thermo Fisher Scientific shares in Q2 2026, an estimated $2.86M.
- Thermo Fisher Scientific made up 0.36% of Carnegie Investment Counsel's portfolio in Q2 2026, its #78 holding.
- Carnegie Investment Counsel first reported a position in Thermo Fisher Scientific in Q4 2017 and has held it in 35 quarters since.
- Carnegie Investment Counsel's Thermo Fisher Scientific position peaked at $36M in Q3 2024.
- 1,172 funds tracked by Wall St. Rank held Thermo Fisher Scientific as of Q2 2026.
Based on Carnegie Investment Counsel's 13F filing for Q2 2026, filed 30 Jul 2026.